Archive for the ‘Crohn's’ Category
Monday, March 3rd, 2008
When treating patients with Crohn's disease, early use of an intensive combined immunosuppression (CI) in combination with conventional management is more effective than the current standard, treatment with corticosteroids. These outcomes were reported in an Article in the February 23, 2008 issue of The Lancet.
Crohn's disease is a gastrointestinal disorder ...
Posted in Crohn's | No Comments »
Tuesday, October 16th, 2007
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) yesterday announced that the U.S. Food and Drug Administration (FDA) informed the companies that the Agency will extend its regulatory review of TYSABRI® (natalizumab) as a treatment for Crohn's disease by up to 3 months.
The companies have been informed by ...
Posted in Crohn's | No Comments »
Monday, July 23rd, 2007
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that they have been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the marketing application for the use of natalizumab in patients with ...
Posted in Crohn's | No Comments »
Monday, April 30th, 2007
Abbott announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA® (adalimumab) for the treatment of severe Crohn′s disease. HUMIRA will be the first self-administered biologic for the treatment of Crohn's ...
Posted in Clinical Trials / Drug Trials, Crohn's, GastroIntestinal | No Comments »
Sunday, April 22nd, 2007
Crohn's disease is a chronic relapsing inflammatory disorder of the intestinal tract that affects an estimated 0.15% of people in the developed world. Common symptoms include abdominal pain and diarrhea, but the disorder is often associated with debilitating clinical complications. Researchers from the University of Liege, Belgium, have now uncovered ...
Posted in Crohn's, Genetics | No Comments »
Friday, April 20th, 2007
An international research team - including investigators from Massachusetts General Hospital (MGH) and the Broad Institute of Harvard University and Massachusetts Institute of Technology - has identified several novel genetic variations associated with the risk of Crohn's disease. One of the identified genes establishes a role for autophagy, a previously ...
Posted in Crohn's, GastroIntestinal, Genetics, Immune System | No Comments »
Friday, April 20th, 2007
A consortium of Canadian and American researchers report in Nature Genetics the results from a search of the entire human genome for genetic risk factors leading to the development of Crohn's disease. Specifically, using a novel approach, the authors identified that the PHOX2B, NCF4 and ATG16L1 genes constitute genetic risk ...
Posted in Crohn's, Genetics | No Comments »
Monday, April 9th, 2007
Ocera Therapeutics Inc. announced today that a Phase 2 exploratory study for AST-120 in patients with active pouchitis was initiated at Cleveland Clinic and that it has also met the 50 percent enrollment target in its pivotal Phase 3 trial of AST-120 in fistulizing Crohn's ...
Posted in Clinical Trials / Drug Trials, Crohn's | No Comments »
Sunday, April 8th, 2007
The first national audit of the care of inflammatory bowel disease (IBD) in the UK has shown marked variation in the resources and quality of care. The UK IBD Audit is the first UK-wide audit in gastroenterology and is a collaborative partnership between gastroenterologists (the British Society of Gastroenterology and ...
Posted in Crohn's, GastroIntestinal | No Comments »
